Cabaletta Bio (NASDAQ:CABA) Trading 10.3% Higher – Should You Buy?

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) shot up 10.3% on Wednesday . The stock traded as high as $3.09 and last traded at $3.21. 1,342,561 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 3,731,450 shares. The stock had previously closed at $2.91.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright improved its EPS forecasts for several periods, including Q3 and Q4 2026, Q1–Q4 2027, FY2026 and FY2027. The firm now expects a loss of $1.35 per share in FY2026 versus its prior forecast of $1.51, and a loss of $1.29 in FY2027 versus $1.48 previously. These narrower projected losses suggest better expected operating performance and are likely supporting sentiment toward Cabaletta Bio (CABA). Cabaletta Bio stock information
• Positive Sentiment: The most significant revision was for FY2028, with HC Wainwright moving its estimate to a $0.74-per-share loss from a $1.41 loss. The firm continues to forecast a transition to profitability by FY2030, with expected earnings of $0.89 per share, reinforcing the longer-term potential of Cabaletta Bio’s pipeline.
• Neutral Sentiment: Despite the upgrades, Cabaletta Bio is still expected to report losses in the coming periods, including approximately $0.31 per share in quarterly losses during late 2026 and early 2027. The current-year consensus remains a loss of $1.34 per share, so investors are likely focused on the pace of improvement rather than near-term profits.
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS forecast to a $0.68 loss from a $0.64 loss and cut its FY2030 earnings forecast to $0.89 from $1.11. These downward long-term revisions temper the bullish impact of the nearer-term upgrades and highlight uncertainty around Cabaletta Bio’s path to sustainable profitability.

Analyst Ratings Changes

CABA has been the subject of a number of research reports. Wells Fargo & Company cut their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Cabaletta Bio in a report on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Wall Street Zen cut Cabaletta Bio from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Cabaletta Bio Trading Up 6.7%

The company has a market capitalization of $526.42 million, a PE ratio of -1.98 and a beta of 3.30. The firm has a fifty day moving average of $2.87 and a two-hundred day moving average of $3.06.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. On average, equities analysts expect that Cabaletta Bio, Inc. will post -1.34 EPS for the current fiscal year.

Institutional Trading of Cabaletta Bio

A number of institutional investors have recently modified their holdings of CABA. Kestra Advisory Services LLC purchased a new position in Cabaletta Bio during the 1st quarter valued at about $32,000. SummitTX Capital L.P. purchased a new stake in Cabaletta Bio in the 1st quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $34,000. Legal & General Group Plc bought a new stake in shares of Cabaletta Bio in the 2nd quarter worth approximately $34,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $38,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.